Interestingly, an increasing CD4+/CD8+ ratio has previously been postulated as a predicator of positive outcome in patients with metastatic melanoma receiving chemo-immunotherapy (combination cytotoxic chemotherapy plus IFN) [49]. This evidence concerns the gene CD8A and metastatic melanoma.